Two counts, one registry: the UK Renal Registry actively tracks roughly 8,000 IgA nephropathy patients against a total estimated prevalence of 10,000 to 15,000, and the gap is a follow-up-intensity question, not a diagnostic one.
The UK Renal Registry gives IgA nephropathy an unusually reliable epidemiological base relative to most rare kidney diseases, because a network of roughly 80 NHS specialist nephrology centres performs the confirmatory biopsies almost every diagnosis requires. The Registry's own reporting implies a total prevalence of 10,000 to 15,000 UK patients, built from approximately 500 new biopsy-confirmed diagnoses each year compounded over the disease's typically decades-long course. Set against that total, the Registry actively tracks roughly 8,000 patients under ongoing nephrology follow-up at any given time, a smaller number by design: patients with stable, low-proteinuria disease are frequently stepped back to primary-care or general-nephrology monitoring rather than kept in the specialist registry's active cohort.
That follow-up gap matters commercially because it is where the novel-agent-eligible population actually sits. IgA nephropathy drives 10 to 12 percent of incident UK end-stage renal disease, roughly 1,000 to 1,200 cases a year, and it is that progression risk that justifies bringing a stable patient back into active follow-up. Once mandatory ACEi/ARB optimisation is applied against the total prevalence base, 3,000 to 5,000 patients remain eligible for a novel agent, the population this deliverable's companion Payer & HTA analysis prices at up to £140 to 180 million a year in potential NHS spend. Fewer than 500 patients currently access any novel therapy ahead of full NICE commissioning, so well under a fifth of the eligible pool is reached today, a penetration gap our sensitivity analysis ranks above the underlying prevalence estimate itself.
UK IgA nephropathy sizing — registry total versus active-follow-up count
| Sizing Method | Population Estimate | Source |
|---|---|---|
| Registry-based (total prevalence) | 10,000–15,000 patients | UK Renal Registry 2023 annual report |
| Active-follow-up-based | ~8,000 patients | UK Renal Registry 2023 annual report |
| ESRD conversion | 10–12% of incident UK ESRD (~1,000–1,200/yr) | UK Renal Registry 2023 annual report |
| Novel-agent-eligible (post-ACEi/ARB gate) | 3,000–5,000 patients; <500 currently treated pre-NICE | Renal Association IgAN guideline 2023; NICE scoping documentation |
Sources: UK Renal Registry 2023 annual report; Renal Association IgA Nephropathy guideline 2023; NICE scope for IgA nephropathy technology appraisals 2024.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- UK Renal Registry methodology and its active-follow-up scope
- the total-prevalence estimate built from the ~500-a-year new-diagnosis rate
- what the follow-up gap means for outreach and identification strategy
Delivers
- ESRD conversion methodology (~1,000-1,200 cases/yr)
- the mandatory ACEi/ARB optimisation gate that defines eligibility
- the pre-NICE access shortfall and what closes it
Delivers
- Sensitivity ranking across every input
- scenario ranges tied to expanded nephrology follow-up capacity
- the assumption most likely to move planning numbers under an internal challenge
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why the active-follow-up count, not the total prevalence estimate, is what most sizing exercises get wrong
- Pressure-tested against the registry-vs-prevalence gap before the rest of the model is built out
- UK Renal Registry's ~500-a-year new biopsy-confirmed diagnosis rate
- The 10,000-15,000-patient total prevalence this implies
- The ~8,000 patients under active nephrology follow-up at any given time
- Cross-check against the registry-based total prevalence estimate
- Where the two counts agree and diverge
- Follow-up-intensity, not diagnostic gap, as the explanation
- 10-12% ESRD conversion rate (~1,000-1,200 cases/yr) and its role in eligibility
- The 3,000-5,000-patient novel-agent-eligible segment and the fewer-than-500 currently treated
- Ranking new-diagnosis rate, follow-up share, and ESRD conversion rate by impact on the total
- Scenario ranges tied to expanded follow-up capacity
- The open sizing questions your team must close before the number is used in planning
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx market sizing model triangulates at least two independent counting methods before accepting a patient number. For the UK, that means the Registry's total-prevalence estimate against its active-follow-up count, distinct from a forecasting or patient-flow model of dynamic uptake.
UK IgA nephropathy sizing sources: the UK Renal Registry 2023 annual report, the Renal Association IgA Nephropathy guideline 2023, and the NICE scope for IgA nephropathy technology appraisals 2024.
- Total prevalence and new-diagnosis rate verified against the UK Renal Registry 2023 annual report
- ESRD conversion rate verified against the UK Renal Registry 2023 annual report
- Novel-agent-eligible segmentation verified against the Renal Association IgAN guideline 2023 and NICE scoping documentation
Frequently asked questions
Commission this model
AXLRx delivers UK IgA nephropathy market sizing models built for forecasting and strategy teams sizing the NHS-eligible opportunity. Custom model in 72 hours.
Specify your indication, target region, and cohort definition.
AXLRx analyst confirms triangulation methods and comparator set before building.
Research-verified sizing model in 72 hours with optional analyst readout.